H1.co Valuation, Funding & Investors

H1.co is valued at $773M as of June 2022.

See full H1.co profile

Last H1.co valuation

$773M

Series C · Jun 2022

Last H1.co funding round

$40M

Undisclosed stage · May 2026

Cumulative funding H1.co raised

$234M

across 5 funding rounds

Key investors in H1.co

  • Menlo Ventures
  • Transformation Capital
  • dRx Capital
  • Y Combinator
  • Lux Capital
  • IVP

H1.co Overview

About H1.co

H1.co is a New York-based healthcare intelligence platform founded in 2017 that aggregates data on over 4 million healthcare professionals and 1,000 institutions. The service enables life sciences companies, hospitals, and health systems to access provider insights, clinical trial matching, and benchmarking tools. H1 connects stakeholders through its HCP Universe database and partners with entities like Pfizer and Mayo Clinic.


Founded

2017

HQ

United StatesNew York City, NY

Website

h1.co

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Valuation

$773M (Jun 2022)

H1.co Valuation

H1.co is currently valued at $773M, based on its Series C in June 2022.

The $23M round included Menlo Ventures, Novartis, Goldman Sachs Asset Management and Transformation Capital.

H1.co's valuation has moved from $773M at its Series C in November 2021 to $773M in June 2022, across 2 priced rounds.

H1.co valuation by funding round

H1.co valuation by funding round
DateStageValuation
Jun 2022Series C$773M
Nov 2021Series C$773M

H1.co Funding History

H1.co has raised a total of $234M across 5 funding rounds.

H1.co's first fundraising round was a $13M Series A in March 2020. The most recent completed round was a $40M undisclosed-stage round in May 2026.

H1.co funding rounds

H1.co funding rounds
DateStageInvestorsRaisedValuationDeal Summary
May 2026Undisclosed stageCVS Health Ventures (lead)$40M-H1 received a $40 million investment in a round led by CVS Health Ventures on May 28, 2026. The round was described as a strategic investment by the corporate venture capital arm of CVS Health, aimed at supporting health care innovation and digital disruption. The announcement did not specify a valuation or deal structure beyond the lead investor and investment amount. The investment follows a prior collaboration between H1 and CVS Health Ventures, which was cited as part of the rationale for the funding. H1 said the capital would support expansion of its AI healthcare data infrastructure and provider-directory capabilities, with an emphasis on making health care information more accessible and useful. CVS Health Ventures was described as a corporate venture fund focused on early-stage and growth-stage companies in health care. H1 is a healthcare data and software company focused on physician and provider data, including AI-enabled products for healthcare provider discovery and infrastructure. The company’s materials and related coverage characterize the business as building data products used to improve access to provider information and support healthcare workflows.
Jun 2022Series CMenlo Ventures; Novartis; Goldman Sachs Asset Management; Transformation Capital$23M$773MH1.co is a health tech platform that connects healthcare professionals, clinical, science, and research information, serving as a massive digital professional database and data analytics platform linking healthcare professionals with life science companies like pharmaceutical, biotech, and medical device firms, essentially functioning as LinkedIn for the pharmaceutical and biotech industries. The company supports over 250 customers, including top pharmaceutical companies, and had grown from under 10 employees as a bootstrapped Y Combinator graduate in January 2020 to more than 600 employees globally by June 2022, with rapid scaling including two acquisitions in the prior year. In June 2022, H1 secured a Series C extension of $23 million in equity plus $10 million in debt, bringing the total Series C to $123 million following the original $100 million round in November 2021 led by Altimeter Capital with participation from Goldman Sachs Asset Management, Menlo Ventures, Transformation Capital, Flex Capital, IVP, Lux Capital, and LeadEdge. This extension maintained the post-money valuation at $773 million on the same terms as the initial Series C close, extending runway amid volatile markets to fuel growth, product development, network expansion, and hiring toward becoming the core global healthcare network. Traction included approximately 140% year-over-year ARR growth as of Q1 2022, with the company on pace to double revenue in 2022 and over 50% growth in less than two quarters post-initial Series C. H1 has raised $305 million across 8 rounds total by 2024, with recognition as an innovator on lists like Forbes' Best Startup Employers 2022 and NYC Digital Health 100.
Nov 2021Series CAltimeter Capital (lead); Menlo Ventures; IVP; Lead Edge Capital; Lux Capital; dRx Capital; Flex Capital; Goldman Sachs Asset Management; Transformation Capital$100M$773MH1 operates a global platform connecting healthcare professionals, providing comprehensive data on doctors worldwide, including public, proprietary, and private sources to help pharma, life sciences, hospitals, and academic centers identify key opinion leaders, clinical research opportunities, and make informed decisions. Products include Explorer, HCP Universe, Trial Landscape, and Carevoyance, serving over 100 clients such as seven of the top 10 pharmaceutical companies like Novartis and AstraZeneca, plus institutions like Columbia and UPenn. On November 16, 2021, H1 raised a $100 million Series C round led by Altimeter Capital, with new investors Goldman Sachs Asset Management and Flex Capital, and participation from existing investors IVP, Menlo Ventures, Transformation Capital, Lux Capital, and Lead Edge Capital. The funding aimed to expand data and network, product development, hiring, and go-to-market efforts to pharma and life sciences. In June 2022, H1 secured a $23 million Series C extension, bringing the total Series C to $123 million at a $773 million valuation, extending runway amid volatile markets at the same terms. At the time of the Series C announcement, H1 reported over 250% year-to-date growth in annual recurring revenue (ARR) in 2021, with about 100 clients and strong traction in its first use case for key opinion leader identification. By Q1 2022, ARR growth reached approximately 140% year-over-year, supported by network effects and increasing demand for healthcare data. The company, which graduated from Y Combinator in 2020 as a bootstrapped startup under 10 employees, had raised about $71 million prior and grown to over 200 employees with offices in 5 global locations across 84 countries. H1's flywheel accelerates with more healthcare professionals and industry engagement, positioning it as a must-have data source in a fast-changing healthcare environment. Investors highlighted the massive opportunity in life sciences data, with the digital health market projected to reach $426.8 billion by 2027.
Dec 2020Series BIVP (lead); Menlo Ventures (lead); Y Combinator; Lead Edge Capital; Lux Capital; dRx Capital; Transformation Capital$58M-H1.co (H1 Insights) is a healthcare data platform described as the LinkedIn for the healthcare industry, maintaining a database of over 8 million healthcare professional profiles. It serves pharmaceutical, biotech, and life sciences companies by enabling connections with healthcare professionals, particularly through services for medical affairs departments. The company graduated from Y Combinator and demonstrated strong growth, with 350% year-over-year increase and 35 pharmaceutical customers as of April 2020. In February 2020, H1 raised $12.9 million in a Series A round led by Menlo Ventures, with participation from Baron Davis Enterprises, ClearPoint Investment Partners, Jeff Hammerbacher, Liquid 2 Ventures, Novartis dRx, and Underscore VC. This funding came shortly after Y Combinator graduation and was not repriced despite the onset of the COVID-19 pandemic, and the company was generating multiple millions of dollars in revenue at the time. H1 continued operations amid COVID-19 disruptions, with pharma companies pausing clinical trials but still engaging medical affairs services. Earlier traction included rapid database expansion and customer adoption, positioning H1 to leverage AI and machine learning for healthcare impact. Plans post-Series A included a massive hiring spree.
Mar 2020Series AMenlo Ventures (lead); Jeff Hammerbacher; ClearPoint Investment Partners; Y Combinator; Liquid 2 Ventures; dRx Capital; Underscore VC; Baron Davis Enterprises$13M-H1 is a healthcare data platform and professional networking service often described as 'LinkedIn for healthcare.' The company maintains digital profiles and data analytics on over 8 million healthcare professionals and 16,000 institutions across 70+ countries, updated weekly, with comprehensive information including expertise, educational history, affiliations, research, publications, clinical trials, patents, and grants. The company's database captures information on over 95% of healthcare professional-patient interactions in the U.S. In February 2020, H1 closed a $12.9 million Series A round led by Menlo Ventures and including investors Novartis DRX, Y Combinator, Baron Davis Enterprises, ClearPoint Investment Partners, Jeff Hammerbacher, Liquid 2 Ventures, and Underscore VC. At the time of the round, H1 reported 350% revenue growth year-over-year and counted over 35 pharmaceutical companies as customers. The company used the capital to expand its sales, product design, and engineering teams, and to pursue expansion into new market segments including hospitals, health systems, and the provider community. By June 2022, H1 had raised a total of $193 million across multiple rounds and achieved a valuation of $773 million in its Series C extension.

Who has invested in H1.co?

17 investors have backed H1.co across its funding rounds, including Menlo Ventures, Transformation Capital, dRx Capital, Y Combinator, Lux Capital and IVP.

Lead investors include CVS Health Ventures, Altimeter Capital, IVP and Menlo Ventures.


H1.co Investors

Investors in H1.co by funding rounds participated
InvestorHQRoundsRoleFirst check
Menlo VenturesUnited StatesSan Francisco, CA4LeadMar 2020
dRx CapitalSwitzerlandBasel3ParticipantMar 2020
Transformation CapitalUnited StatesBoston, MA3ParticipantDec 2020
IVPUnited StatesSan Francisco, CA2LeadDec 2020
Y CombinatorUnited StatesSan Francisco, CA2ParticipantMar 2020
Lead Edge CapitalUnited StatesNew York City, NY2ParticipantDec 2020
Lux CapitalUnited StatesNew York City, NY2ParticipantDec 2020
Goldman Sachs Asset ManagementUnited StatesNew York City, NY2ParticipantNov 2021
Jeff HammerbacherUnited StatesUnited States1ParticipantMar 2020
ClearPoint Investment PartnersUnited StatesSan Francisco, CA1ParticipantMar 2020
Liquid 2 VenturesUnited StatesSan Francisco, CA1ParticipantMar 2020
NovartisSwitzerlandBasel1ParticipantJun 2022
Altimeter CapitalUnited StatesSan Francisco, CA1LeadNov 2021

This data is available for Pro users. Sign up to see all 17 H1.co investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by H1.co

H1.co has acquired 5 companies to date.

Last acquisition by H1.co was on September 9th 2026. H1.co acquired Defacto Health for undisclosed valuation.


Latest Acquisitions by H1.co

Defacto Health
VEDA Data Solutions
Ribbon Health
Faculty Opinions
Description
Healthcare data transparency
VEDA Data Solutions is a Washington, D.C.-headquartered provider of automated data science and machine learning platforms for healthcare payers and provider networks. Founded in 2015, it integrates predictive analytics into existing dashboards for risk stratification, utilization forecasting, and population health management. VEDA processes claims, EHR, and social determinants data to deliver models for readmission prevention and care gap closure. The platform supports Medicare Advantage plans and ACOs, deploying solutions at organizations like Humana and regional health systems.
Ribbon Health is a New York-headquartered healthcare API platform delivering provider data to payers and digital health firms. It maintains directories with verified credentials, specialties, and availability for 1.5 million U.S. clinicians. Ribbon Health powers referrals, prior authorizations, and navigation apps for Aetna and Teladoc partners.
Faculty Opinions is a literature curation service where over 8,000 life sciences experts select and annotate key research articles. Launched as part of the F1000 ecosystem, it covers biology, medicine, and clinical research with detailed commentary on methodologies and implications. The platform organizes publications into collections by topic and provides researcher-validated recommendations. Cambridge-based, Faculty Opinions aids scientists in navigating high-impact studies efficiently.
HQ CountryUnited StatesUnited StatesUnited StatesUnited Kingdom
HQ City
Washington, DC
Madison, WI
New York City, NY
London
Deal Date9 Sep 20263 Jun 202512 Dec 202416 Feb 2022
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all H1.co acquisitions and their M&A valuation multiples.

Start Free Trial

H1.co Competitors

H1.co competitors include listed companies like Clover Health and SOPHiA Genetics, and private ones like Proof, Nansen, Elixir and Codat.

Public and private companies comparable to H1.co
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Clover HealthUnited StatesUnited StatesPublicly listed$1.9B($84M)$2.4B0.8x
ProofUnited StatesBoston, MAPrivate--$760M-
NansenSingaporeSingaporePrivate--$750M-
ElixirUnited StatesNew York City, NYPrivate--$800M-
SOPHiA GeneticsSwitzerlandSwitzerlandPublicly listed$77M($65M)$726M7.5x
CodatUnited KingdomLondonPrivate--$825M-

H1.co Public Comps

H1.co is still privately-owned, but its public comps include SOPHiA Genetics, Veradigm, CARE Ratings, GlobalData, Bayzed Health Group, Finatext, Yidu Tech, TaiDoc Technology, Omada Health and Certara.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
SOPHiA Genetics$77M($65M)8.8x7.5x(10.4x)(18.8x)
Veradigm$588M$54M0.9x0.9x9.8x6.8x
CARE Ratings$49M$21M9.2x9.9x21.5x20.5x
GlobalData$433M$140M1.7x1.7x5.3x5.0x
Bayzed Health Group$167M$18M3.0x-28.4x-
Finatext$71M$13M6.3x5.4x34.1x-
Yidu Tech$122M($4M)1.4x1.2x(45.0x)7.7x
TaiDoc Technology$132M$58M2.1x-4.8x-

This data is available for Pro users. Sign up to see all H1.co competitors and their valuation data.

Start Free Trial

Common questions about H1.co

When was H1.co founded?H1.co was founded in 2017.
Where is H1.co headquartered?H1.co is headquartered in New York City, NY, United States.
Is H1.co publicly listed?No, H1.co is a private, VC-backed company.
What is H1.co's valuation?H1.co was last valued at $773M in its Series C in June 2022.
How much funding has H1.co raised?H1.co has raised $234M across 5 funding rounds.
What was H1.co's last funding round?H1.co's last funding round was a $40M undisclosed-stage round in May 2026, led by CVS Health Ventures.
Who are H1.co's investors?H1.co's investors include Menlo Ventures, dRx Capital, Transformation Capital, IVP, Y Combinator, Lead Edge Capital, Lux Capital, Goldman Sachs Asset Management, Jeff Hammerbacher, ClearPoint Investment Partners and 7 others.
Which companies are comparable to H1.co?Companies comparable to H1.co include Clover Health, Proof, Nansen, Elixir, SOPHiA Genetics and Codat.
How many companies has H1.co acquired?H1.co has acquired 5 companies, including Defacto Health, VEDA Data Solutions, Ribbon Health, Faculty Opinions and Carevoyance.

See companies similar to H1.co

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial